MADRIGAL PHARMACEUTICALS INC's ticker is MDGL and the CUSIP is 558868105. A total of 207 filers reported holding MADRIGAL PHARMACEUTICALS INC in Q3 2023. The put-call ratio across all filers is 0.38 and the average weighting 0.3%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2023 | $15,689 | -4.8% | 67,918 | -0.2% | 0.05% | -10.0% |
Q1 2023 | $16,479 | -68.2% | 68,025 | -61.9% | 0.06% | -67.7% |
Q4 2022 | $51,814 | -99.8% | 178,518 | +93.6% | 0.19% | +148.0% |
Q2 2018 | $25,785,000 | +266.7% | 92,193 | +53.1% | 0.08% | +257.1% |
Q1 2018 | $7,031,000 | -25.1% | 60,200 | -41.1% | 0.02% | -22.2% |
Q4 2017 | $9,384,000 | – | 102,242 | – | 0.03% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Tao Capital Management LP | 77,657 | $5,047,000 | 3.31% |
L1 Capital Pty Ltd | 161,163 | $10,474,000 | 2.05% |
Avoro Capital Advisors LLC | 1,535,000 | $99,760,000 | 1.84% |
Affinity Asset Advisors, LLC | 100,000 | $6,499,000 | 1.81% |
GREAT POINT PARTNERS LLC | 95,500 | $6,207,000 | 1.50% |
ARMISTICE CAPITAL, LLC | 1,236,000 | $80,328,000 | 1.39% |
Affinity Asset Advisors, LLC | 75,000 | $4,874,000 | 1.36% |
MPM BioImpact LLC | 44,747 | $2,908,000 | 0.69% |
Baker Brothers Advisors | 1,499,213 | $97,434,000 | 0.64% |
Perceptive Advisors | 331,023 | $21,513,000 | 0.62% |